Indeed, dysregulation of HER3 trafficking, as well as the ability of this receptor to interact with other receptor tyrosine kinases to modulate the sensitivity of targeted therapeutics in different cancers, has prompted the use of anti‐HER3 antibodies, both as single agent or in combination with anti‐cancer drugs to overcome resistance (Chakrabarty et al, 2012; Abel et al, 2013; Ma et al, 2014; Capone et al, 2015; Gaborit et al, 2016; Black et al, 2019). Here, NTRK1 is linked to cancer.